1. E. M. Blass, E. Fitzgerald, and P. Kehoe, “Interactions between Sucrose, Pain and Isolation Distress.” Pharmacology, Biochemistry and Behavior 26 (1986): 483-489.
2. K. DesMaisons, Potatoes Not Prozac. New York: Simon & Schuster, 1998.
3. P. F. Sullivan, et al., “Total Cholesterol and Suicidality in Depression.” Biological Psychiatry 36 (1994): 472-477.
4. P. Godfrey, B. Toone, M. Carney, et al., “Enhancement of Recovery from Psychiatric Illness by Methylfolate.” Lancet 336 (1990): 392-395.
5. I. Bell, J. Edman, F. Morrow, et al., “B Complex Vitamin Patterns in Geriatric and Young Adult Inpatients with Major Depression.” Journal of the American Geriatrics Society 39 (1991): 252-257.
6. B. W. Penninx, J. M. Guralnik, et al., “Vitamin B12 Deficiency and Depression in Physically Disabled Older Women: Epidemiologic Evidence from the Women’s Health and Aging Study.” American Journal of Psychiatry 157 (May 2000): 715-721.
7. B. J. Kaplan, et al., “Effective Mood Stabilization with a Chelated Mineral Supplement: An Open-Label Trial in Bipolar Disorder.” Journal of Clinical Psychiatry 62 (2001): 936-944; A. B. Mayer, “Historical Changes in the Mineral Content of Fruits and Vegetables.” British Food Journal. 99 (1997): 207-211; C. W. Popper, “Do Vitamins or Minerals (Apart from Lithium) Have Mood-Stabilizing Effects?” Journal of Clinical Psychiatry 62, no. 12 (2001): 933-944; S. J. Schoenthaler and I. D. Bier, “The Effect of Vitamin-Mineral Supplementation on Juvenile Delinquency Among American Schoolchildren: A Randomized, Double-Blind Placebo-Controlled Trial.” Journal of Alternative and Complementary Medicine 6 (February 2000): 7-17.
8. S. T. Marcolina, “Food for Thought: Organic.” Alternative Medicine Alert 6, no. 7 (2003): 73-78; National Research Council, Pesticides in the Diets of Infants and Children. Washington, DC: National Academy Press, 1993; U.S. Environmental Protection Agency, “Pesticides.” available at www.epa.gov/ pesticides; Environmental Working Group, “Foods You’ll Want to Buy Organic.” available at www.foodnews.org/highpesticidefoods.php; V. Klinkenborg, “A Farming Revolution: Sustainable Agriculture.” National Geographic, December 1995; 60-89; A. B. Mayer, “Historical Changes in the Mineral Content of Fruits and Vegetables.” British Food Journal 99 (1997): 207-211; P. Mader, et al., “Soil Fertility and Biodiversity in Organic Farming.” Science 296 (2002): 1694-1697; K. Woese, et al., “A Comparison of Organically and Conventionally Grown Foods: Results of a Review of the Relevant Literature.” Journal of Food and Agriculture 74 (1995): 281-293; V. Worthington, “Nutritional Quality of Organic Versus Conventional Fruits, Vegetables and Grains.” Journal of Alternative Complementary Medicine 2 (April 2001): 161-173.
1. I. Bell, J. Edman, F. Morrow, et al., “Brief Communication: Vitamin B1, B2 and B6 Augmentation of Tricyclic Antidepressant Treatment in Geriatric Depression with Cognitive Dysfunction.” Journal of the American College of Nutrition 11 (1992): 159-163.
2. P. Godfrey, B. Toone, M. Carney, et al., “Enhancement of Recovery from Psychiatric Illness by Methylfolate.” Lancet 336 (1990): 392-395.
3. T. T. Baldewicz, K. Goodkin, et al., “Cobalamin Level Is Related to Self-Reported and Clinically-Rated Mood and to Syndromal Depression in Bereaved HIV-1+ and HIV-1- Homosexual Men.” Journal of Psychosomatic Research 48, no. 2, (2000): 177-185.
4. B. W. Penninx, J. M. Guralnik, et al., “Vitamin B12 Deficiency and Depression in Physically Disabled Older Women: Epidemiologic Evidence from the Women’s Health and Aging Study.” American Journal of Psychiatry 157 (May 2000): 715-721.
5. J. Hintikka, T. Tolmunen, et al., “High Vitamin B12 Level and Good Treatment Outcome May Be Associated in Major Depressive Disorder.” BMC Psychiatry. 3 (December 2, 2003): 17.
6. J. McBride, “Can Foods Forestall Aging?” Agricultural Research. 47, no. 2 (February 1999): 15-17.
7. D. Benton and R. Cook, “The Impact of Selenium Supplementation on Mood.” Biological Psychiatry 29 (1991): 1092-1098.
8. C. W. Popper, “Do Vitamins or Minerals (Apart from Lithium) Have Mood-Stabilizing Effects?” Journal of Clinical Psychiatry 62, no. 12 (2001): 933-944.
9. See for example, A. Tanskanen, J. R. Hibbeln, J. Tuomilehto, et al., “Fish Consumption and Depressive Symptoms in the General Population in Finland.” Psychiatric Services 52, no. 4 (2001): 529-531.
10. A. P. Simopoulos, “Overview of Evolutionary Aspects of Omega-3 Fatty Acids in the Diet.” World Review of Nutrition and Dietetics 83 (1998): 1-11.
11. L. A. Horrocks and Y. K. Yeo, “Health Benefits of Docosahexaenoic Acid (DHA).” Pharmacological Research 40, no. 3 (1999): 211-225.
12. T. Hamazaki, et al., “The Effect of Docosahexaenoic Acid on Aggression in Young Adults: A Placebo-Controlled Double-Blind Study.” Journal of Clinical Investigation 97 (1996): 1129-1133.
13. K. S. Vaddadi, P. Courtney, et al., “A Double-Blind Trial of Essential Fatty Acid Supplementation In Patients with Tardive Dyskinesia.” Psychiatry Research 27 (3) (1989): 313-323.
14. A. L. Stoll, et al., “Omega-3 Fatty Acids in Bipolar Disorder: A Preliminary Double-Blind, Placebo-Controlled Trial.” Archives of General Psychiatry 56 (May 1999): 407-412.
15. M. Maes, A. Christophe, J. Delanghe, et al., “Lowered Omega-3 Polyunsaturated Fatty Acids in Serum Phospholipids and Cholesteryl Esters of Depressed Patients.” Psychiatry Research 85 (1999): 275-291.
16. M. Maes and R. S. Smith, “Fatty Acids, Cytokines and Major Depression.” Biological Psychiatry 43, no. 5 (1998): 313-314.
17. J. R. Hibbeln, et al., “Essential Fatty Acids Predict Metabolites of Serotonin and Dopamine in Cerebrospinal Fluid Among Healthy Control Subjects, and Early- and Late-Onset Alcoholics.” Biological Psychiatry 44 (1998): 235-242.
18. W. F. Byerly, et al., “5-HTP: A Review of Its Antidepressant Efficacy and Adverse Effects.” Journal of Clinical Psychopharmacology 7 (1987): 127-137.
19. L. J. Van Hiele, “1-5-HTP in Depression: The First Substitution Therapy in Psychiatry?” Neuropsychobiology 6 (1980): 230-240.
20. W. Poldinger, et al., “A Functional-Dimensional Approach to Depression: Serotonin Deficiency as a Target Syndrome in a Comparison of 5-HTP and Fluvoxamine.” Psychopathology 24 (1991): 53-81.
21. H. M. van Praag and S. de Haan, “Depression Vulnerability and 5-Hydroxytryptophan Prophylaxis.” Psychiatry Research 3 (1980): 75-83; H. M. van Praag, “In Search of the Mode of Action of Antidepressants: 5-HTP/Tyro-sine Mixtures in Depression.” Advances in Biochemical Psychopharmacology 39 (1984): 301-314; H. M. van Praag and R. S. Kahn, “L-5-Hydroxytryptophan in Depression and Anxiety.” Schweizerische Rundschau fur Medizin Praxis 77, no. 34A (1998): 40-46.
22. H. Sabelli, “Amino Acid Precursors for Depression.” Psychiatric Times (October 2000): 42-49; H. C. Sabelli and A. D. Mosnaim, “Phenylethylamine Hypothesis of Affective Behavior.” American Journal of Psychiatry 131, no. 6 (1974): 695-699; H. C. Sabelli, et al., “Sustained Antidepressant Effect of PEA Replacement.” Journal of Neuropsychiatry Clinical Neurosciences 8, no. 2 (1996): 168-171; W. Birkmayer, et al., “L-Deprenyl Plus L-Phenylalanine in the Treatment of Depression.” Journal of Neural Transmission 59, no. 1 (1984): 81-87. H. C. Sabelli, “Phenylethylamine Replacement as a Rapid and Physiological Treatment for Depression.” Psycheline 2, no. 3 (1998): 32-39.
23. D. B. Menkes, D. C. Coates, and J. P. Fawcett, “Acute Tryptophan Depletion Aggravates Premenstrual Syndrome.” Journal of Affective Disorders 329, no. 1 (1994): 37-44.
24. “S-Adenyl-L-Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease.” Evidence Report/Technology Assessment 64 (October 2002): 1-194; R. P. Brown, P. Gerbarg, and T. Bottiglieri, “S-Adenylmethionine (SAMe) for Depression.” Psychiatric Annals 32, no. 1 (2002): 29-44.
25. K. M. Bell, L. Plon, et al., “S-adenosylmethionine Treatment of Depression: A Controlled Clinical Trial.” American Journal of Psychiatry 145, no. 9 (1988): 1110-1114.
26. R. P. Brown, P. Gerbarg, and T. Bottiglieri, “S-adenylmethionine (SAMe) for Depression.” Psychiatric Annals 32, no. 1 (2002): 29-44.
27. J. Lake, “Psychotropic Medications from Natural Products: A Review of Promising Research and Recommendations.” Alternative Therapies 6, no. 3 (2000): 36-60; B. Gaster and J. Holroyd, “St. John’s Wort for Depression: A Systematic Review.” Archives of Internal Medicine 160 (January 24, 2000): 152-156; E. Shrader, “Equivalence of St. John’s Wort Extract and Fluoxetine: A Randomized, Controlled Study in Mild-Moderate Depression.” International Clinical Psychopharmacology 15, no. 2 (2000): 61-68; L. Taylor and K. A. Kobak, “An Open-Label Trial of St. John’s Wort in Obsessive Compulsive Disorder.” Journal of Clinical Psychiatry 61 (August 2000): 575-578; J. R. T. Davidson and K. M. Connor, “St. John’s Wort in Generalized Anxiety Disorder: Three Case Reports.” Journal of Clinical Psychopharmacology 21 (2001): 635-636.
28. E.-P. Barrette, “St. John’s Wort for the Treatment of Depression: An Update.” Alternative Medicine Alert 6, no. 3 (2003): 25-30; U. Werneke, O. Horn, and D. M. Taylor. “How Effective is St. John’s Wort? The Evidence Revisited.” Journal of Clinical Psychiatry 65, no. 5 (May 2004): 611-617.
29. R. C. Shelton, M. B. Keller, et al., “Effectiveness of St. John’s Wort in Major Depression: A Randomized Controlled Trial.” Journal of the American Medical Association 285 (April 18, 2001): 1978-1986; Hypericum Depression Trial Study Group, “Effect of Hypericum perforatum (St. John’s Wort) in Major Depressive Disorder: A Randomized Controlled Trial.” Journal of the American Medical Association 287 (April 10, 2002): 1807-1814.
30. B. J. Diamond and S. C. Shiflett, “Ginkgo Biloba Extract: Mechanisms and Clinical Indications.” Archives of Physical Medicine and Rehabilitation 81 (May 2000): 668-678; A. Fugh-Berman, Alternative Medicine: What Works. Tucson, Ariz.: Odonian Press, 1996, pp. 114-116; J. Lake, “Psychotropic Medications from Natural Products: A Review of Promising Research and Recommendations.” Alternative Therapies 6, no. 3 (2000): 36-60.
31. P. L. Le Bars, M. M. Katz, et al., “A Placebo-Controlled, Double-Blind, Randomized Trial of an Extract of Ginkgo biloba for Dementia.” Journal of the American Medical Association 278 (1997): 1327-1332.
32. P. Le Bars, et al., “A 26-Week Analysis of a Double-Blind, Placebo-Controlled Trial of the Ginkgo Biloba Extract EGb 761 in Dementia.” Dementia and Geriatric Cognitive Disorders 11, no. 4 (2000): 230-237.
33. A. J. Cohen and B. Bartlik, “Ginkgo Biloba for Antidepressant-Induced Sexual Dysfunction.” Journal of Sex and Marital Therapy 24, no. 2 (1998): 139-144.
1. J. Greist, M. Klein, et al., “Antidepressant Running: Running as Treatment for Nonpsychotic Depression.” Behavioral Medicine 5 (1978): 19-24.
2. I. L. McCann and D. S. Holmes, “Influence of Aerobic Exercise on Depression.” Journal of Personality and Social Psychology 46, no. 5 (1984): 1142-1147.
3. J. A. Blumenthal, M. A. Babyak, K. A. Moore, et al., “Effects of Exercise Training on Older Adults with Major Depression.” Archives of Internal Medicine 159 (1999): 2349-2356.
4. M. Babyak, J. A. Blumenthal, S. Herman, et al., “Exercise Treatment for Major Depression: Maintenance of Therapeutic Benefit at Ten Months.” Psychosomatic Medicine 62 (2000): 633-638.
5. Based on recommendations from the Centers for Disease Control and Prevention, the American College of Sports Medicine, and the Institute of Medicine.
6. A. C. King and R. F. Oman, et al., “Moderate-Intensity Exercise and Self-Rated Quality of Sleep in Older Adults. A Randomized Controlled Trial.” Journal of the American Medical Association 277 (1997): 32-37.
7. D. Brown, “Valerian Root: Nonaddictive Alternative for Insomnia and Anxiety.” Review of Natural Medicine (Fall 1994): 221-224.
8. F. Donath, S. Quispe, et al., “Critical Evaluation of the Effect of Valerian Extract on Sleep Structure and Sleep Quality.” Pharmacopsychiatry 33 (2000): 47-53.